PDF
ePub
Citation
Print
Abstract
Purpose:
To evaluate the effect of portal hypertension on the tumor recurrence in patients with hepatocellular carcinoma (HCC) and without hepatic decompression following radiofrequency ablation (RFA).
Materials and Methods:
Treatment-naïve HCC patients within the Milan criteria and with Child-Pugh class A were included in this study, who had performed RFA in our hospital between January 2010 and March 2017. Univariate and multivariate analyses using the Cox proportional hazard model were performed to find the predictors of local or distant tumor recurrence.
Results:
Overall, 178 patients were included in this study. Median follow-up period was 40.2 months. The difference in the local tumor progression rates depending on the absence or presence of portal hypertension was not statistically significant (p = 0.195). The 1-, 3-, and 5-year distant intrahepatic tumor spread rates were 6.6%, 29.5%, and 537% in patients without portal hypertension, and 23.4%, 51.9%, and 63.6% in patients with portal hypertension, respectively. The difference was statistically significant (p = 0.011). Univariate and multivariate analysis showed that portal hypertension was an independent predictor for distant intrahepatic tumor spread (p = 0.008).
REFERENCES
1.El-Serag HB., Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999. 340:745–750.
2.Lok AS. Hepatitis B: liver fibrosis and hepatocellular carcinoma. Gastroenterol Clin Biol. 2009. 33:911–915.
3.Sakurai T., Kudo M., Umemura A., He G., Elsharkawy AM., Seki E, et al. p38α inhibits liver fibrogenesis and consequent he-patocarcinogenesis by curtailing accumulation of reactive oxygen species. Cancer Res. 2013. 73:215–224.
4.Kim MY., Baik SK., Yea CJ., Lee IY., Kim HJ., Park KW, et al. Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis. Eur J Gastroenterol Hepatol. 2009. 21:1241–1246.
5.Thabut D., Moreau R., Lebrec D. Noninvasive assessment of portal hypertension in patients with cirrhosis. Hepatology. 2011. 53:683–694.
6.Choi JW., Chung JW., Lee DH., Kim HC., Hur S., Lee M, et al. Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma. Eur Radiol. 2018. 28:2184–2193.
7.Bruix J., Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011. 53:1020–1022.
8.European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012. 56:908–943.
9.Shiina S., Tateishi R., Arano T., Uchino K., Enooku K., Nakagawa H, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012. 107:569–577. quiz 578.
10.Peng ZW., Lin XJ., Zhang YJ., Liang HH., Guo RP., Shi M, et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology. 2012. 262:1022–1033.
11.Nakazawa T., Kokubu S., Shibuya A., Ono K., Watanabe M., Hi-daka H, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol. 2007. 188:480–488.
12.Lee DH., Lee JM., Lee JY., Kim SH., Yoon JH., Kim YJ, et al. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. Radiology. 2014. 270:900–909.
13.Kei SK., Rhim H., Choi D., Lee WJ., Lim HK., Kim YS. Local tumor progression after radiofrequency ablation of liver tumors: analysis of morphologic pattern and site of recurrence. AJR Am J Roentgenol. 2008. 190:1544–1551.
14.Bezerra AS., D'Ippolito G., Faintuch S., Szejnfeld J., Ahmed M. Determination of splenomegaly by CT: is there a place for a single measurement? AJR Am J Roentgenol. 2005. 184:1510–1513.
15.Perri RE., Chiorean MV., Fidler JL., Fletcher JG., Talwalkar JA., Stadheim L, et al. A prospective evaluation of computerized tomographic (CT) scanning as a screening modality for esophageal varices. Hepatology. 2008. 47:1587–1594.
16.Lee CM., Jeong WK., Lim S., Kim Y., Kim J., Kim TY, et al. Diagnosis of clinically significant portal hypertension in patients with cirrhosis: splenic arterial resistive index versus liver stiffness measurement. Ultrasound Med Biol. 2016. 42:1312–1320.
17.Forner A., Llovet JM., Bruix J. Hepatocellular carcinoma. Lancet. 2012. 379:1245–1255.
18.Bruix J., Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005. 42:1208–1236.
19.Lang EV., Chen F., Fick LJ., Berbaum KS. Determinants of intravenous conscious sedation for arteriography. J Vasc Interv Radiol. 1998. 9:407–412.
20.Lupescu I., Masala N., Capsa R., Câmpeanu N., Georgescu SA. CT and MRI of acquired portal venous system anomalies. J Gastrointestin Liver Dis. 2006. 15:393–398.
21.Curley SA., Marra P., Beaty K., Ellis LM., Vauthey JN., Abdalla EK, et al. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg. 2004. 239:450–458.
22.Tublin ME., Dodd GD 3rd., Baron RL. Benign and malignant portal vein thrombosis: differentiation by CT characteristics. AJR Am J Roentgenol. 1997. 168:719–723.
23.Li C., Hu J., Zhou D., Zhao J., Ma K., Yin X, et al. Differentiation of bland from neoplastic thrombus of the portal vein in patients with hepatocellular carcinoma: application of susceptibility-weighted MR imaging. BMC Cancer. 2014. 14:590.
24.Catalano OA., Choy G., Zhu A., Hahn PF., Sahani DV. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology. 2010. 254:154–162.
25.Kang TW., Rhim H., Lee MW., Kim YS., Choi D., Lim HK. Terminology and reporting criteria for radiofrequency ablation of tumors in the scientific literature: systematic review of compliance with reporting standards. Korean J Radiol. 2014. 15:95–107.
26.Ahmed M., Solbiati L., Brace CL., Breen DJ., Callstrom MR., Char-boneau JW, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria—a 10-year update. J Vasc Interv Radiol. 2014. 25:1691–1705. .e4.
27.Ghany MG., Kleiner DE., Alter H., Doo E., Khokar F., Promrat K, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology. 2003. 124:97–104.
28.Ismail MH., Pinzani M. Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepat Med. 2011. 3:69–80.
29.Gieling RG., Burt AD., Mann DA. Fibrosis and cirrhosis reversibility - molecular mechanisms. Clin Liver Dis. 2008. 12:915–937.
30.Okuda K., Ohtsuki T., Obata H., Tomimatsu M., Okazaki N., Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985. 56:918–928.
31.Cho KC., Patel YD., Wachsberg RH., Seeff J. Varices in portal hypertension: evaluation with CT. Radiographics. 1995. 15:609–622.
Fig. 1
The difference in the recurrence rates depending on the presence of clinically relevant portal hypertension after radiofrequency ablation of hepatocellular carcinoma. A. Local tumor progression rates were similar between the two curves (p = 0.195). B, C. Distant intrahepatic tumor recurrence rates (B), and overall tumor progression rates were statistically higher in patients with clinically relevant portal hypertension (C) (p = 0.011 and p = 0.003, respectively). Note that the curves for distant intrahepatic recurrence and overall tumor progression were nearly identical. HTN = hypertension, RFA = radiofrequency ablation
Table 1.
The Baseline Characteristics of Patients. Group 1 and Group 2 Denote thoses Patients without and with Portal Hypertension, and there are 82 and 96 Patients in Each Group, Respectively
Table 2.
Univariate Analysis of Prognostic Factors for Recurrence-Free Survival
XML Download